arXiv:2408.02600v3 Announce Type: replace Abstract: Background. Biomedical language models should improve performance on biomedical text while retaining general-language-modeling fluency. For Mamba-based models, this trade-off has not been systematically studied across biomedical literature and clinical text. Methods. We developed BioMamba, a family of biomedical Mamba2 models at five scales obtained by continued pretraining of released public Mamba2 checkpoints on a balanced 80%/10%/10% mixture of PubMed abstracts, the Colossal Clean Crawled Corpus (C4), and Wikipedia. The contribution is the
The development of BioMamba comes as Mamba-based models gain traction for their efficiency and as there's a growing need for domain-specific AI in fields like biomedicine where accuracy and fluency are critical.
This development is important for strategic readers as it signifies progress in creating specialized AI models that can better process and understand complex scientific texts, potentially accelerating discovery and application in critical sectors.
The ability to systematically adapt efficient Mamba-based models to biomedical literature and clinical text with optimized fluency-performance trade-offs means that AI tools for drug discovery, diagnostics, and research will become more sophisticated and reliable.
- · Biomedical researchers
- · Pharmaceutical companies
- · AI model developers
- · Healthcare sector
Improved performance of AI models on biomedical and clinical texts for tasks like information extraction and hypothesis generation.
Accelerated drug discovery processes and more accurate diagnostic tools due to enhanced understanding of scientific literature by AI.
The proliferation of highly specialized AI assistants and agents within healthcare and life sciences, leading to significant shifts in knowledge work in these fields.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.CL